Teva Pharmaceutical Industries (TEVA) Other financing activities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Other financing activities for 18 consecutive years, with -$1.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other financing activities fell 200.0% year-over-year to -$1.0 million; the trailing twelve-month figure through Jun 2026 stood at $73.0 million (up 386.67% YoY), and the FY2025 full-year result was $41.0 million, up 612.5% from the prior year.
• Other financing activities retreated to -$1.0 million in Q2 2026 per TEVA's latest filing, from $36.0 million in the prior quarter.
• Across five years, Other financing activities topped out at $40.0 million in Q4 2025 and bottomed at -$76.0 million in Q3 2023.
• Historically, Other financing activities has averaged -$15.4 million across 5 years, with a median of -$3.0 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Other financing activities tumbled 4100.0% in 2022, then jumped 1100.0% in 2026.
• Over 5 years, Other financing activities stood at -$3.0 million in 2022, then sank by 2433.33% to -$76.0 million in 2023, then jumped by 114.47% to $11.0 million in 2024, then surged by 263.64% to $40.0 million in 2025, then sank by 102.5% to -$1.0 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered -$1.0 million, $36.0 million, and $40.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.